Columbia targets Sirtuin 1 in the prostate cancer that escapes treatment fastest

Neuroendocrine prostate cancer is not just another footnote in prostate oncology. It is an aggressive form of the disease that behaves differently from more common prostate tumors, and once a tumor shifts into a neuroendocrine program, the clinical options can narrow quickly. That is why a new study from researchers at Columbia University Irving Medical Center, published through work in the Journal of Experimental Medicine, matters: it does not merely describe another molecular change, but points to a specific target, Sirtuin 1.

According to the summary reported by MedicalXpress, the Columbia team identified a gene that drives the development of neuroendocrine prostate cancer, or NEPC. That gene is Sirtuin 1, commonly shortened to SIRT1, a regulatory protein involved in controlling cellular processes. The central claim is not simply that SIRT1 appears in the disease landscape. The study shows that genetic or pharmacological inhibition of Sirtuin 1 prevents NEPC tumors from growing in mice. That distinction matters: a biomarker helps read disease, but a therapeutic target has to show that the disease changes when the target is pressed.

The finding is still preclinical. It is not a ready-made treatment for patients, and mouse data should not be compressed into a slogan about a drug that "prevents cancer." But the result carries weight because NEPC remains one of the harder edges of prostate cancer treatment. If tumor growth can genuinely be stopped by blocking Sirtuin 1, then researchers have a rational path for inhibitor development, dose testing, safety work and, only after that, human clinical studies.

The setting also matters. Columbia University Irving Medical Center in New York has serious translational medicine infrastructure, and publication in JEM gives the signal more weight than a loose conference claim. Still, the cleanest reading is disciplined: Columbia has shown that Sirtuin 1 is functionally important in mouse NEPC tumors and that blocking it can prevent their growth. The next question is not whether this can support a large headline, but whether the mechanism can be translated safely and consistently into human disease.

For patients and clinicians, this is still a distant but concrete development. Instead of a vague promise of a "new approach," the work offers a named molecular target, experimental evidence in an animal model and a clear reason for further study. In a field where aggressive tumors often move faster than the available treatments, that is the kind of finding that should not end with a press summary. It is where the harder work begins.